Search Within

Advanced Practice Providers

  1. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (69)
  2. Journal Article (25)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (95)
  2. Department of Medicine (95)
  3. Hematologic Malignancies Research (95)
  4. Hematologic Malignancies, Division of (95)
  5. Nursing (80)
  6. GSK Faculty (79)

More Groups

People
  1. Renier Brentjens (52)
  2. Elizabeth Halton (48)
  3. Jae Park (46)
  4. Isabelle Riviere (38)
  5. Gunjan Shah (33)
  6. Maria Palomba (33)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (5)
  4. 2022 (4)
  5. 2021 (9)
  6. 2020 (13)

More Years

Publications
  1. Blood (38)
  2. Journal of Clinical Oncology (16)
  3. Biology of Blood and Marrow Transplantation (7)
  4. Blood Advances (4)
  5. Hematological Oncology (3)
  6. Molecular Therapy (3)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. American Society of Clinical Oncology (16)
  3. Elsevier Inc. (9)
  4. Nature Publishing Group (7)
  5. American Association for Cancer Research (5)
  6. Wiley Blackwell (4)

More Publishers

Results (95)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Continuous mobile wearable bio-monitoring of newly diagnosed multiple myeloma patients undergoing initial chemotherapy
    Meeting Abstract

    Tavitian, E.; Mastey, D.; Salcedo, M.; Zarski, A.; Chansakul, A.; Diab, V.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity
    Meeting Abstract

    Smith, M.; Littmann, E. R.; Slingerland, J. B.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Schluter, J.; Park, J. H.; O'Cearbhaill, R.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Neurotoxicity associated with CD19-specific chimeric antigen receptor T cell therapy for adult acute lymphoblastic leukemia (B-ALL)
    Meeting Abstract

    Santomasso, B.; Park, J. H.; Riviere, I.; Mead, E.; Li, D.; Senechal, B.; Purdon, T.; Halton, E.; Diamonte, C.; Sadelain, M.; more...
    Neurology (2018)

    Fulltext@MSK | Save
  • Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia
    Journal Article

    Santomasso, B. D.; Park, J. H.; Salloum, D.; Riviere, I.; Flynn, J.; Mead, E.; Halton, E.; Wang, X.; Senechal, B.; Purdon, T.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Autologous CD19-Targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Journal Article

    Geyer, M. B.; Rivière, I.; Sénéchal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Halton, E.; Lamanna, N.; more...
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy - A preliminary report
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M.; Rusch, V.; O'Cearbhaill, R.; Ngai, D.; Chintala, N.; Halton, E.; Diamonte, C.; Modi, S.; Solomon, S.; more...
    Molecular Therapy (2018)

    Fulltext@MSK | Save